Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Novartis    NOVN   CH0012005267

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets

Novartis : and UC Berkeley collaborate to tackle 'undruggable' disease targets

share with twitter share with LinkedIn share with facebook
share via e-mail
10/02/2017 | 10:17am CET

Release date- 29092017 - Basel, Switzerland - Novartis has joined forces with researchers from the University of California, Berkeley, to develop new technologies for the discovery of next generation therapeutics, pursuing the vast number of disease targets in cancer and other illnesses that have eluded traditional small molecule compounds and are considered 'undruggable.'

'Novartis pioneers new therapeutic paradigms, creating definitive medicines for life-threatening diseases,' said Jay Bradner, President of the Novartis Institutes for BioMedical Research. 'Our Berkeley alliance powerfully extends our ability to advance discovery of molecules aimed at the historically inaccessible drug targets.'

The collaboration establishes the Novartis-Berkeley Center for Proteomics and Chemistry Technologies, based in existing labs at Berkeley, and includes support for joint research projects between Novartis and Berkeley scientists. The projects harness covalent chemoproteomics technology that rapidly maps locations on protein targets-including those that have been considered 'undruggable'-where compounds could form lasting bonds while providing starting points for novel therapeutics.

'Never before have we been able to explore what we call the proteome, the totality of over 20,000 proteins in the body, with such breadth, depth and speed,' said covalent chemoproteomics expert Daniel Nomura, Director of the Center and Associate Professor of Chemistry, of Molecular and Cell Biology, and of Nutritional Sciences and Toxicology at Berkeley. 'Combining technology advances in proteomics and chemistry allows us to imagine creating compounds to bind every known protein in the body, especially those underlying serious diseases such as cancer.'

The alliance will also explore the potential of emerging therapeutics known as degraders, which involve the use of bifunctional molecules that bind to disease targets on one end and on the other end to a key component in a cell's natural protein-disposal system. The collaborators plan to test whether the covalent chemoproteomics technology could aid in reducing the time required to create potential degraders from years to months.

'Traditional drug compounds bind to proteins at places that cause them to malfunction, but many disease targets lack these functional binding locations,' said John Tallarico, Head of Chemical Biology and Therapeutics at NIBR. 'Degraders are different because they can bind to disease targets at non-functional sites and trigger the destruction of the target proteins, resulting in the interference of their function.'

Other aspects of the collaboration include screening natural product compounds and using the covalent chemoproteomics system to discover their targets, understanding mechanism of action and developing new platform technology enabling the discovery of compounds to bind to greater numbers of proteins.


This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as 'to tackle,' 'aims,' 'next-generation,' 'pioneers,' 'aimed,' 'to explore,' 'potential,' 'can,' 'will,' 'plan,' 'could,' 'investigational,' or similar terms, or by express or implied discussions regarding the aims of the collaboration with UC Berkeley, regarding potential new platform technology or products arising from the collaboration with UC Berkeley, , or regarding potential future revenues from such new platform technology or products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the collaboration with UC Berkeley will be successful or achieve its intended goals. Neither can there be any guarantee that any new platform technology or investigational products will result from the collaboration. Nor can there be any guarantee that any investigational products resulting from the collaboration will be submitted or approved for sale in any market, or at any particular time. Nor can there be any guarantee that such new platform technology or products will be commercially successful in the future. In particular, our expectations regarding such new platform technology and products could be affected by, among other things, the success of the collaboration with UC Berkeley, our ability to effectively deploy and use any new platform technology arising from the collaboration, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures; general economic and industry conditions, including the effects of the persistently weak economic and financial environment in many countries; safety, quality or manufacturing issues, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Novartis

Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving generic and biosimilar pharmaceuticals and eye care. Novartis has leading positions globally in each of these areas. In 2016, the Group achieved net sales of USD 48.5 billion, while R&D throughout the Group amounted to approximately USD 9.0 billion. Novartis Group companies employ approximately 119,000 full-time-equivalent associates. Novartis products are sold in approximately 155 countries around the world.


Tel: +41 61 324 2200

Email: [email protected]

(c) 2017 Electronic News Publishing -, source ENP Newswire

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on NOVARTIS
01/16 NOVARTIS : new data reinforces superiority of Cosentyx® versus Stelara®* in achi..
01/16 NOVARTIS : Sandoz regulatory submission for proposed biosimilar adalimumab accep..
01/16 NOVARTIS : Sandoz regulatory submission for proposed biosimilar adalimumab accep..
01/12 Drugmakers see a pricing blueprint in an $850,000 gene therapy
01/12 Pfizer's Barrett named CEO of Novartis Oncology
01/11 NOVARTIS : Axcella Announces Appointment of David Epstein, Former CEO of Novarti..
01/11 NOVARTIS : Patent Issued for Mechanical Support of an Indirect Contact Lens by a..
01/11 NOVARTIS : Researchers Submit Patent Application, "Pim Kinase Inhibitor Combinat..
01/11 NOVARTIS : Researchers at Novartis Describe Findings in Pure Red-Cell Aplasia (T..
More news
News from SeekingAlpha
01/16 FDA launches new program to boost transparency of clinical data used to suppo..
01/16 Novartis' Cosentyx beats Janssen's Stelara in head-to-head psoriasis study
01/16 Sandoz files U.S. marketing application for Humira biosimilar
01/13 YOUR DAILY PHARMA SCOOP : Lipocine's Gloomy Future, Puma Labeling Change, Concer..
01/12 Novartis poaches Pfizer exec to head oncology unit
Financials ($)
Sales 2017 49 186 M
EBIT 2017 11 774 M
Net income 2017 7 499 M
Debt 2017 17 692 M
Yield 2017 3,27%
P/E ratio 2017 25,15
P/E ratio 2018 21,91
EV / Sales 2017 4,95x
EV / Sales 2018 4,74x
Capitalization 226 B
Duration : Period :
Novartis Technical Analysis Chart | NOVN | CH0012005267 | 4-Traders
Technical analysis trends NOVARTIS
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 30
Average target price 88,8 $
Spread / Average Target 2,4%
EPS Revisions
Joseph Jimenez Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Kirsch Chief Financial Officer
Vasant Narasimhan Chief Medical Officer & Head-Drug Development
Srikant Madhav Datar Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS1.38%225 838
JOHNSON & JOHNSON4.32%391 587
ROCHE HOLDING LTD.-0.85%218 350
PFIZER0.88%217 804
AMGEN6.41%134 322